ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial

被引：0
作者：
David A. Drew
Samantha M. Chin
Katherine K. Gilpin
Melanie Parziale
Emily Pond
Madeline M. Schuck
Kathleen Stewart
Meaghan Flagg
Crystal A. Rawlings
Vadim Backman
Peter J. Carolan
Daniel C. Chung
Francis P. Colizzo
Matthew Freedman
Manish Gala
John J. Garber
Curtis Huttenhower
Dmitriy Kedrin
Hamed Khalili
Douglas S. Kwon
Sanford D. Markowitz
Ginger L. Milne
Norman S. Nishioka
James M. Richter
Hemant K. Roy
Kyle Staller
Molin Wang
Andrew T. Chan
机构：
[1] Massachusetts General Hospital and Harvard Medical School,Clinical and Translational Epidemiology Unit, Department of Medicine
[2] Massachusetts General Hospital and Harvard Medical School,Division of Gastroenterology, Department of Medicine
[3] The Ragon Institute of MGH,McCormick School of Engineering
[4] MIT and Harvard,Department of Biostatistics
[5] Northwestern University,Department of Epidemiology
[6] Broad Institute,Eicosanoid Core Laboratory, Division of Clinical Pharmacology
[7] Harvard T.H. Chan School of Public Health,Section of Gastroenterology
[8] Harvard T.H. Chan School of Public Health,Channing Division of Network Medicine, Department of Medicine
[9] Case Western Reserve University School of Medicine and University Hospitals of Cleveland,Division of Gastroenterology and Clinical and Translational Epidemiology Unit
[10] Vanderbilt University,undefined
[11] Boston Medical Center,undefined
[12] Brigham and Women’s Hospital and Harvard Medical School,undefined
[13] Massachusetts General Hospital,undefined
来源：
Trials | / 18卷
关键词：
Aspirin; Colorectal cancer; Biomarker; Chemoprevention;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 452 条
  • [1] Siegel RL(2016)Cancer statistics, 2016 CA Cancer J Clin 66 7-30
  • [2] Miller KD(2016)Aspirin and colorectal cancer: the promise of precision chemoprevention Nat Rev Cancer 16 173-86
  • [3] Jemal A(2008)Liquid chromatography-tandem mass spectrometric quantification of the dehydration product of tetranor PGE-M, the major urinary metabolite of prostaglandin E(2) in human urine J Chromatogr B Analyt Technol Biomed Life Sci 871 72-7
  • [4] Drew DA(2006)Celecoxib for the prevention of sporadic colorectal adenomas N Engl J Med 355 873-84
  • [5] Cao Y(2003)Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial Gastroenterology 125 328-36
  • [6] Chan AT(2013)Urinary prostaglandin metabolites (PGE-M) are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs Gastroenterology 144 S-145-75
  • [7] Neale JR(2004)Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer Anal Biochem 334 266-42
  • [8] Dean BJ(2007)Aspirin and the risk of colorectal cancer in relation to the expression of COX-2 N Engl J Med 356 2131-58
  • [9] Bertagnolli MM(2009)Aspirin use and survival after diagnosis of colorectal cancer JAMA 302 649-10
  • [10] Eagle CJ(2013)Urinary PGE-M: a promising cancer biomarker Cancer Prev Res 6 507-6
12345678910